Clinical trials: Infliximab
Ulcerative Colitis, Efficacy, Self
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
Endocopic remission rates of moderate to severe ulcerative colitis are low. Biologics including Vedolizumab, infliximab, and adalimumab are effective in induction and maintainence of ulcerative colitis.
- Conditions
- Ulcerative Colitis, Efficacy, Self, Biologics, Mesalazine
- Trial name
- NCT05205603
- Testing
- Infliximab, Vedolizumab, Mesalazine
- Where
- 11 sites in China
- Volunteers
- 438 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Sterile Corneal Melt
Topical Infliximab for Sterile Corneal Melt
Corneal melt is a complication that could affect very ill eyes and lead to the thinning of the cornea (the clear window covering of the eyes).
- Trial name
- NCT02987686
- Testing
- Topical Infliximab
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Infliximab, Infusion
Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease
OBJECTIVES OF THE STUDY 1. Investigate whether there are just as few infusion reactions with infliximab infusions of 60 min and 30 min. 2. Investigate patient and nurse satisfaction with infusions of 60 min and 30 min. 3.
- Conditions
- Infliximab, Infusion, IBD (Inflammatory Bowel Disease), Patient Satisfaction
- Trial name
- iRAPID (NCT06839820)
- Testing
- Infusion rate of infliximab
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- University Hospital, Akershus
Glaucoma Following Surgery
Topical Infliximab in Eyes With Penetrating Keratoplasty
Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma.
- Trial name
- NCT05180994
- Testing
- Topical infliximab, No topical infliximab
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Acute Severe Ulcerative Colitis
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）
This clinical trial aims to evaluate the comparative efficacy and safety of upadacitinib versus infliximab as second-line treatments for acute severe ulcerative colitis, addressing the following key questions: (1) Can…
- Trial name
- NCT07550673
- Testing
- upadacitinib, Infliximab
- Where
- 4 sites in China
- Volunteers
- 226 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Kidney Transplantation
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
The aim of the study is to evaluate the efficacy of new immunosuppressive protocol based on two applications of anti-CD52 MabCampath (Alemtuzumab) a single dose of anti-TNF-α Remicade (infliximab) monoclonal antibodies in the…
- Trial name
- NCT02711202
- Testing
- MabCampath,, Remicade, Sirolimus
- Volunteers
- 20 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Melanoma
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma
This is a Phase 1b, open-label study of immune checkpoints inhibitors Nivolumab+Ipilimumab administered in combination with the anti-TNF-α either Infliximab or Certolizumab, in patients with advanced melanoma.
- Trial name
- TICIMEL (NCT03293784)
- Testing
- Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab, Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut Claudius Regaud
Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)
Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
To study the efficacy of different biological treatment on patient with inflammatory bowel disease after one year of treatment in upper egypt
- Trial name
- NCT07495644
- Testing
- adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab
- Volunteers
- 95 people
- Sponsor
- Assiut University
Takayasu Arteritis
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or…
- Trial name
- NCT07491913
- Testing
- Tociliuzumab, Infliximab, Adalimumab
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Crohn Disease, Infliximab
Combined Immunosuppression for Pediatric Crohn's Disease
This is a randomized controlled trial to compare the efficacy and safety of infliximab and immunosuppressives therapy alone or in combination for pediatric Crohn's disease.
- Conditions
- Crohn Disease, Infliximab, Immunosuppression, Children, Only
- Trial name
- NCT05043870
- Testing
- Infliximab and immunosuppressives, Infliximab
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Children's Hospital of Fudan University
IBD (Inflammatory Bowel Disease)
MICI-BIO: Study on Patient With Chronic Inflammatory Bowel Disease
This is a monocentric, non-profit prospective cohort study with longitudinal biological sampling. The study will include patients with IBD starting biological therapy with infliximab.
- Trial name
- MICI-BIO (NCT07470502)
- Testing
- Infliximab level analysis in biological samples
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Meyer Children's Hospital IRCCS
Crohn Disease
Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease, with many of those being young children and adolescents.
- Trial name
- REMODEL (NCT04974099)
- Testing
- RoadMAB precision dashboard, Infliximab precision dosing
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Crohn Disease, Ulcerative Colitis
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
The OPTIMIZE Trial compares whether iDose dashboard-driven infliximab dosing (iDose-driven dosing) is more effective and safer than standard infliximab dosing for inducing and maintaining disease remission in inflammatory bowel…
- Conditions
- Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
- Trial name
- NCT04835506
- Testing
- Infliximab
- Where
- 25 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- Beth Israel Deaconess Medical Center
Crohn's Diseases, Crohn's Disease in Pediatric Patient
The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
The goal of this clinical trial is to investigate whether there are significant differences in the efficacy of infliximab monotherapy and combined azathioprine therapy in treating pediatric Crohn's disease, as well as whether…
- Trial name
- NCT07424040
- Testing
- Infliximab combined with azathioprine therapy, Infliximab monotherapy
- Where
- 4 sites in China
- Volunteers
- 154 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Crohn's Disease
Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
This study aims to evaluate whether the combination of palmitoleic acid with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.
- Trial name
- NCT07417696
- Testing
- Palmitoleic Acid + Infliximab, Infliximab
- Volunteers
- 400 people
- Sponsor
- Chinese Medical Association
Crohn's Diseases
Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
This study aims to evaluate whether the combination of Akkermansia muciniphila with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.
- Trial name
- NCT07415473
- Testing
- Infliximab, Akkermansia muciniphila + Infliximab
- Volunteers
- 400 people
- Sponsor
- Chinese Medical Association
Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Approximately 30% of patients with rheumatoid arthritis have an inadequate response to anti-TNF (primarily or loss of response), leaving two alternatives: rotation to a second anti-TNF or change of biologic, with a different…
- Trial name
- ROC (NCT01000441)
- Testing
- infliximab, etanercept, adalimumab, abatacept, rituximab or tocilizumab
- Where
- 44 sites in France, Monaco
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Rheumatoid Arthritis
Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis
The purpose of this study is to assess the efficacy, safety and pharmacokinetics of maintenance treatment with 3mg/kg, 6mg/kg or 10mg/kg of TA-650 in combination with methotrexate (MTX) after three infusions (weeks-0, 2, 6) of…
- Trial name
- NCT00691028
- Testing
- TA-650 3 mg/kg, TA-650 6 mg/kg, TA-650 10 mg/kg
- Volunteers
- 327 people
- Sponsor
- Tanabe Pharma Corporation
Crohn's Disease
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
The purpose of this study is to assess the efficacy, safety and pharmacokinetics after administration of 10mg/kg TA-650 every 8 weeks to patients with Crohn's disease showing an insufficient response to previous treatment with 5…
- Trial name
- NCT00805766
- Testing
- TA-650
- Where
- 4 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Tanabe Pharma Corporation
Pediatric Crohn's Disease
Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
The purpose of this study is to evaluate the efficacy of TA-650 using Pediatric Crohn's Disease Activity Index (PCDAI) in pediatric patients with moderate to severe Crohn's disease after TA-650 administration at a dose of 5 mg/kg…
- Trial name
- NCT01580670
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Tanabe Pharma Corporation